



ELSEVIER



# All-atom virus simulations

Jodi A Hadden and Juan R Perilla

The constant threat of viral disease can be combated by the development of novel vaccines and therapeutics designed to disrupt key features of virus structure or infection cycle processes. Such development relies on high-resolution characterization of viruses and their dynamical behaviors, which are often challenging to obtain solely by experiment. In response, all-atom molecular dynamics simulations are widely leveraged to study the structural components of viruses, leading to some of the largest simulation endeavors undertaken to date. The present work reviews exemplary all-atom simulation work on viruses, as well as progress toward simulating entire virions.

## Address

Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, United States

Corresponding author: Hadden, Jodi A ([jhadden@udel.edu](mailto:jhadden@udel.edu))

**Current Opinion in Virology** 2018, **31**:82–91

This review comes from a themed issue on **Virus structure and expression**

Edited by **Kay Grunewald** and **Thomas Krey**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 1st September 2018

<https://doi.org/10.1016/j.coviro.2018.08.007>

1879-6257/© 2018 Elsevier B.V. All rights reserved.

## Introduction

Viruses are a constant threat to human health, as well as the health of our domesticated animals and agriculture. Often, viral infections are challenging to treat due to limited therapeutic options. Although vaccines are effective at preventing or reducing the severity of viral disease, protective vaccines against fewer than 20 different viruses are currently available (WHO). Further, the high mutation rates of some viruses necessitate that vaccines be updated annually, or that new antiviral treatments be constantly realized to continue disease management in chronically infected individuals.

The rational development of novel prophylactic and therapeutic interventions against viral pathogens depends on detailed knowledge of virus structure, infection cycle processes, and the conformational dynamics that link structures to their functional roles in these processes.

All-atom molecular dynamics (MD) simulations, often referred to as the ‘computational microscope’, remain the only method capable of elucidating the dynamical properties of biomolecules within their physiological environments at full chemical resolution [1]. Modern supercomputers and MD simulation codes enable researchers to investigate the nuances of virus structure and dynamics, even for very large components of virus structure [2].

Most all-atom MD simulation studies of viruses have focused on their protein-based components, particularly envelope proteins, viroporins, capsids, and accessory proteins or enzymes. Some work has leveraged MD simulations to construct complete atomistic models of viral proteins or their assemblies by integrating experimental data. Other work has taken advantage of MD simulations to characterize, under native conditions, the chemical-physical properties of such structures through analysis of their dynamics and influence on surrounding solvent. The overarching goals of virus simulation endeavors are to reveal critical aspects of virus structure or mechanistic insights into their function that can be targeted for novel disease treatments. Here, exemplary all-atom simulations of viruses are briefly reviewed, and progress toward simulating entire virions at atomistic detail is discussed.


## Envelope proteins

The first stage of viral infection is cell entry. Often, this process begins with adhesion of the virus to the host cell via receptor binding. In enveloped viruses, receptor binding is mediated by membrane-embedded surface proteins, which typically also represent the major antigens of the virus and may participate in virus–host membrane fusion. Other envelope proteins play a role in viral egress. The motivation to elucidate the molecular determinants of receptor recognition, as well as the antigenic and fusogenic properties of envelope proteins, have rendered them of great interest for study with MD simulations.

A broadly studied viral envelope protein is the influenza A hemagglutinin (HA) trimer (Figure 1a), which is responsible for cellular adhesion and membrane fusion. Much work on HA has been aimed at understanding its specificity for host cell receptor glycans, which is an important factor in the avian-human transmission barrier [6,7]. Characterization of receptor binding may support the development of adhesion-inhibiting drugs.

All-atom MD simulations have been applied to numerous crystal complexes of HAs with receptor analogues to

Figure 1



Schematic illustrations of viruses whose protein components have been heavily studied using all-atom MD simulations. **(a)** Influenza A virus virion, average diameter of 120 nm [3]. Hemagglutinin (HA), neuraminidase (NA), and the matrix protein 2 viroporin (M2) are embedded within the viral envelope, which surrounds the matrix protein 1 (M1) assembly and encloses the RNA. **(b)** Mature HIV-1 virion, average diameter of 145 nm [4]. The envelope protein (Env) and viroporin (Vpu) are embedded within the viral envelope, which surrounds the matrix protein assembly and encloses the RNA-containing capsid. The virus also carries copies of a protease and reverse transcriptase (RT). **(c)** STMV virion, diameter of 17 nm [5]. STMV is a non-enveloped virus, composed only of the RNA-containing capsid.

characterize binding mode dynamics, as well as to study recognition and specificity based on bound receptor conformations and interaction profiles [8–12]. Recent modeling and simulation work has also revealed that HA receptor specificity may depend on extended glycan structure and the ability to accommodate bidentate binding to biantennary glycans [13,14]. MD simulations have been further employed to evaluate the effects of HA mutations that alter receptor binding and specificity [15,16] and to study HA-antibody recognition and escape [17,18].

Notably, HA is glycosylated, with *N*-glycans contributing around 20% of its molecular weight [6]. All-atom simulations of glycosylated HAs have been used to probe the influence of glycosylation on receptor binding [19], to provide insight into accessibility of glycan-remodeling enzymes [20], and to characterize interactions between HA and lung surfactant protein D, an innate immune lectin that neutralizes influenza A via attachment to HA glycans [21].

HA initiates fusion of the viral envelope and host membranes following cell adhesion and endocytosis, when endosomal acidification triggers it to undergo a conformational change. The mechanism of HA-mediated membrane fusion has been extensively studied with simulation approaches, including characterization of fusion peptide dynamics, interactions with the host membrane, and structural effects of reduced pH [22–32].

The secondary surface antigen of the influenza A virus is the neuraminidase (NA) tetramer (Figure 1a), which cleaves host cell glycans to allow escape of progeny

virions. Several compounds that mimic the native substrate of NA and bind to inhibit its action have been licensed for use as antiviral drugs for the treatment of influenza A (i.e. tamivir and zanamivir) [33]. The majority of simulation work on NA has focused on exploiting it as a drug target. In some cases, all-atom simulations have been employed to characterize the conformational dynamics of NA from the perspective of designing novel drug compounds or elucidating the determinants of ligand recognition and inhibition [34–37]. In other cases, simulations of NA have been used as part of computational screening protocols to discover new druggable hot spots or inhibitor leads [38–40]. Additional studies have provided insights into the mechanisms of drug resistance [41–43], the role of calcium in NA stability and drug binding [44], and the structural basis for increased virulence of NA stalk-deletion mutants [45].

Another well-studied envelope protein is the human immunodeficiency virus type 1 (HIV-1) envelope (Env) trimer (Figures 1b and 2 d), which mediates cellular adhesion and membrane fusion. All-atom MD simulations have been employed to characterize the conformational properties of Env, particularly its V3 variable domain, a critical determinant of CD4 receptor binding [46,47]. Other simulation work on Env has focused on identifying correlated motions that may underlie allosteric communication networks within the protein [47–50]. The transmembrane domain and fusion peptide of Env have also been extensively investigated with MD simulations to explore conformational variability and membrane interactions, providing insights into the mechanism of membrane fusion [51–56].

Importantly, Env is heavily glycosylated, with *N*-glycans accounting for roughly 50% of its molecular weight [57]. These glycans form a shield around Env, cloaking it from the host immune system, and may also influence the binding affinity of CD4. The glycan shield is of great interest as a target for broadly-neutralizing antibody and vaccine design [57], and can only be accurately described with simulations that encompass chemical detail. Several all-atom MD studies have investigated the effects of glycosylation on the conformation and dynamics of Env variable domains V1, V2, and V3, as well as implications for receptor and antibody binding [58–60]. More recent work has used computational modeling and simulation to produce fully glycosylated Env trimers, with the goals of characterizing the dynamical behavior of the glycan shield and determining its impact on antibody elicitation, recognition, and binding [50,61\*,62,63].

Beyond influenza A and HIV-1, all-atom MD simulations have also been applied to study the envelope proteins of several other viruses. Such work has included investigations of the effects of varying pH on the dengue virus [64–69] and vesicular stomatitis virus (VSV) [70] envelope proteins, structure and host membrane interactions for the Ebola virus [71–73] and herpes simplex virus (HSV) [74] envelope protein fusion peptides, solution dynamics of human parainfluenza virus type 3 (HPIV-3) hemagglutinin-neuraminidase [75], and conformational flexibility in the hepatitis C virus (HCV) E2 envelope protein [76,77].

### Viroporins

Enveloped viruses can encode another class of membrane-embedded proteins, called viroporins, that play diverse roles in their respective viral infection cycles. Viroporins are small, hydrophobic proteins that oligomerize within the envelope to form hydrophilic channels, capable of transporting ionic species and small molecules [78]. The essential activities of these channels, their druggability, and potential as models to understand transport mechanisms within the human cell, have rendered them of long-standing interest for study with MD simulations.

The most widely studied viroporin, from a computational perspective, is the influenza A matrix protein 2 (M2) ion channel (Figure 1a), which transports protons across the viral envelope following endosomal acidification to prepare the particle for host membrane fusion and subsequent genome release [79]. All-atom MD simulations have been broadly employed to study M2 channel activation, gating, and proton permeation [80–86], as well as investigate the relationship between pH and channel conductance [87,88] and internal water structure [89]. Adamantane drug compounds (i.e. amantadine and rimantidine) are known to inhibit M2 channel activity [79]. Additional all-atom MD simulation work on M2 has

been aimed at characterizing drug binding and channel inhibition [84,85,90], probing the mechanisms of drug resistance [91,92], and designing new inhibitors against drug-resistant mutants [93,94].

Other viroporins that have been examined using all-atom MD simulations include the viral protein U (Vpu) of HIV-1 (Figures 1b and 2 a). Various early modeling and simulation studies of Vpu [95] led to evaluation of its preferred oligomeric state and all-atom investigation of its dynamics and channel activity [96]. All-atom simulations were also applied to develop a model for the Paramecium bursaria chlorella virus type 1 (PBCV-1) Kcv potassium channel to probe structure–function relationships [97,98] and elucidate its mechanism of ion transport [99]. More recently, all-atom simulations were employed to determine the structure of the hepatitis C virus (HCV) p7 viroporin monomer [100] and to model various channel oligomer states, enabling characterization of their dynamics and conductance properties [101\*,102,103,104,105].

### Capsids

Many viruses package their genome within a remarkable protein shell called a capsid. Often, capsids play key functional roles in delivering the viral genome to the host cell nucleus, rendering them of great interest as drug targets. Capsids generally represent the largest protein components of virus structures, and simulations of intact capsids have accounted for the most substantial all-atom virus simulations yet published [106,2]. Work by Perilla *et al.* has clearly demonstrated the need for chemical detail to facilitate accurate simulation studies of virus capsids as drug targets [107\*\*].

The first all-atom simulation of a complete virus capsid was based on satellite tobacco mosaic virus (STMV, Figures 1c and 2 g) and encompassed a landmark particle count of 1 million atoms with solvent [108\*]. Both an empty and genome-containing capsid were investigated over 10–13 ns. With packaged RNA, the simulated capsid maintained structural integrity and exhibited only minor deviations from icosahedral symmetry. Without RNA, the simulated capsid rapidly broke symmetry and began to implode. The results of the work strongly suggest that RNA is responsible for nucleating assembly of STMV virions.

Prior to work on STMV, simulations of complete capsids were approximated using rotational symmetry boundary conditions, which exploit the icosahedral symmetry of capsid structures to model, at least in effect, a complete capsid using only the capsid asymmetric unit [106]. As time has progressed, all-atom simulations of intact capsids have become increasingly accessible. Notably, such work has included characterization of the stress-response of the southern bean mosaic virus (SBMV) capsid [109], validation of multi-scale modeling approaches based on the

Sesbania mosaic virus (SeMV) capsid [110], derivation of a complete atomic model for the rabbit hemorrhagic disease virus (RHDV) capsid [111], and examination of the interplay between solvent and ions and the porcine circovirus type 2 (PCV2) capsid [112,113].

The first all-atom simulation of a virus capsid to explore the microsecond timescale was based on an empty model of satellite tobacco necrosis virus (STNV), which encompassed 1.2 million atoms with solvent [114<sup>•</sup>]. Like many non-enveloped plant viruses, STNV exhibits specific binding sites for divalent ions, likely calcium, and has been shown experimentally to undergo structural expansion unless these ions are bound. Simulations with and without bound calcium confirmed that the former maintain a smaller diameter and the latter swell. The results of the work produced an atomistic model for the swollen STNV capsid, which was not previously available, as well as an atomistic description of the dynamics underlying the swelling process.

The empty poliovirus capsid was studied over a timescale of 200 ns, based on a system of 6 million atoms with solvent [115]. Simulation results revealed that the capsid functions as a semipermeable membrane structure, translocating water molecules, but not ions, in equilibrium across its surface. Further, the solution pressure on the interior of the capsid was found to be negative, owing to electrostatic interaction of solution electrolytes with the charged capsid surface. The results of the work demonstrate that the capsid plays an essential role in maintaining an environment conducive to the stable accommodation of its RNA genome and associated counterions.

The empty hepatitis B virus (HBV) capsid was simulated for 1.1  $\mu$ s based on a model of the complete assembly domain, derived from crystallography and molecular modeling [116<sup>••</sup>]. The simulation encompassed 6 million atoms with solvent and revealed that the capsid undergoes notable asymmetric distortion at equilibrium. Further, the capsid exhibited a fivefold preference to translocate sodium over chloride through its triangular pores, and induced the localization of sodium along its interior surface. The results of the work implicate the triangular pores as the extrusion site of the capsid's carboxy-terminal domain tails, which contain cellular signals, and suggest a mechanism by which the capsid could modulate signal exposure based on tail phosphorylation. Simulations have also been used to investigate the effects of small-molecule drugs on HBV capsid morphology [107<sup>••</sup>] and to determine the structural basis for enhanced assembly and drug resistance in HBV capsid mutants [117].

An all-atom structure of the human immunodeficiency virus type 1 (HIV-1) capsid (Figures 1b and 2 e) was derived by combining results from cryo-EM and NMR experiments with computational modeling and data-

guided MD simulations [118<sup>••</sup>]. This landmark simulation endeavor, encompassing 64 million atoms with solvent, overcame the challenges of HIV-1 capsid size and asymmetric architecture to generate the first chemically complete model. The results of the study revealed key structural elements defining pentamer-hexamer and hexamer-hexamer interfaces within the capsid and produced a much-needed platform to enable investigation of capsid function and targeted drug development. Notably, the all-atom model has been used to study capsid interactions with the host cell factors cyclophilin A [119,120] and MxB [121], which regulate and restrict HIV-1 viral infectivity, respectively.

In a subsequent study, the empty HIV-1 capsid model was simulated for 1.2  $\mu$ s, setting the current published record for the most substantial all-atom simulation ever performed [122<sup>••</sup>]. The simulation revealed that the capsid translocates chloride across its surface at twice the rate of sodium through ion-specific channels, which may relate to the translocation of nucleotides during reverse transcription. Further, the capsid exhibited complex dynamics, including collective motions that divide the structure into two hemispheres and suggest a mechanism for capsid uncoating, as well as oscillatory surface waves at four different frequencies that may underlie emergent properties of the capsid.

### Immature particle lattices

Retroviruses such as HIV-1, human T-cell leukemia virus type 1 (HTLV-1), and Rous sarcoma virus (RSV) initially assemble as immature particles from Group-specific antigen (Gag) polyproteins. During maturation, proteolytic processing of Gag yields cleavage products that reassemble to produce mature virions [123]. All-atom simulations proved invaluable in determining the structures of the immature HTLV-1 [124] and RSV [125] Gag lattices, as well as the HIV-1 capsid protein-SP1 peptide maturation intermediate (CA-SP1) [126<sup>•</sup>]. Notably, simulations revealed that the CA-SP1 six-helix bundle exists in a dynamic helix-coil equilibrium, and that maturation-inhibiting drugs and mutations act by stabilizing a helical form of the bundle [126<sup>•</sup>]. MD studies of CA-SP1 bound to inositol phosphates showed that these small molecules facilitate the formation of the six-helix bundle and, thus, promote assembly of the Gag lattice [127<sup>•</sup>]. Simulations of the RSV lattice model were used to determine the effects of charge distribution and mutations on Gag assembly [128].

### Viral enzymes

Some viruses encode and package enzymes necessary to carry out the processes that drive their infection cycles. All-atom MD simulations of the HIV-1 protease (Figures 1b and 2 b), which is responsible for proteolytic cleavage of Gag prior to maturation, revealed the motion of the enzyme's active-site flaps, whose opening and

closing are considered essential to function [129–134]. Further, studies of the West Nile virus (WNV) NS3 protease identified a conformational selection mechanism used to identify its substrate [135]. Additionally, all-atom simulations were instrumental in elucidating the mechanism by which non-nucleoside reverse transcription inhibitors (NNRTIs), an important class of therapeutics against HIV-1, interfere with the virus' reverse transcriptase [136] (Figures 1b and 2c), which synthesizes DNA from the RNA template.

### Toward all-atom simulations of complete virions

As experimental methods, particularly cryo-EM and cryo-ET, continue to provide greater detail on virus composition and architecture, and as supercomputers and simulation codes continue to offer greater performance for the study of large biological systems, the computational community becomes poised to study the dynamics of complete virions within physiological environments. Nonetheless, the paucity of accurate, full-length, and fully atomistic models for some major components of virus structure presents a significant challenge to the derivation and investigation of all-atom virions.


Importantly, the lack of accurate all-atom models for encapsidated genome structures is the foremost limiting factor for the construction of complete virions. While the work of Freddolino *et al.* on genome-containing STMV (Figure 1c) represents the only all-atom simulation of a complete virion performed to date [108<sup>\*</sup>], the genome structure employed was not based on the actual STMV RNA sequence. Similarly, a complete pariacoto virus (PaV) virion derived using molecular modeling included an RNA model based on an artificial RNA sequence [137]. For both of these virions, limitations in determining genome organization from crystal structures, which typically rely on icosahedral averaging, led to inaccuracies in the resulting RNA models [138,139]. Recently, Zeng *et al.* used computational methods to generate the first all-atom model for the complete structure of any virus using the natural genome sequence, that of STMV containing realistic RNA [5<sup>\*</sup>].

Moving forward, modeling and simulation will continue to play an essential role in the determination of all-atom structures for genome-containing capsids, particularly through approaches that integrate experimental data from techniques such as NMR and cryo-EM [140,141]. Although simulation studies of the intact HBV capsid have shown that the inherent flexibility of some virus structures may limit the ability to obtain true atomic (1–2 Å) resolution with cryo-EM [116<sup>\*\*</sup>], advances in image processing are enabling high-resolution asymmetric reconstructions capable of producing more authentic descriptions of encapsidated genome, such as those obtained for the immature HBV particle and

bacteriophage MS2 [142,143]. The availability of more complete structural information, along with improved understanding of genome organization within capsids [144] and integrative modeling approaches [1<sup>\*</sup>] that employ increasingly accurate protein and nucleic acid force fields [145,146], will support new simulation studies of all-atom virions in the near future, particularly for non-enveloped viruses.

All-atom simulations of enveloped viruses will face the additional challenge of treating the envelope membrane lipid bilayer. Due to size, complex lipid compositions, and the inclusion of membrane-embedded surface proteins, viral envelopes require careful consideration to model and equilibrate [147]. Further, enclosing a virus capsid in a fully atomistic envelope will significantly increase system size and simulation expense, particularly given the inclusion of solvent. Figure 2 emphasizes the dramatic size disparity between several protein-based components of HIV-1 that have been previously investigated with all-atom simulations and a model of the intact envelope membrane (Figure 2f). The envelope necessarily dwarfs the HIV-1 capsid, the simulations of which currently represent the most far-reaching accomplishment of computational virology reported for structures of atomic detail [118<sup>\*\*</sup>,122<sup>\*\*</sup>]. Following construction of a complete HIV-1 virion, it is clear that substantial supercomputing power will be required to simulate such a colossal biological assembly at chemical resolution, especially over time-scales sufficient to allow meaningful study.

Figure 2



Graphical size comparison of viral protein components. (a) HIV-1 viroporin (Vpu), transmembrane domain. (b) HIV-1 protease. (c) HIV-1 reverse transcriptase (RT). (d) HIV-1 envelope protein (Env) ectodomain. (e) HIV-1 capsid. HIV-1 envelope membrane. (g) STMV capsid.

In the meantime, three viral envelopes have been investigated using coarse-grained simulation methods, including that of an immature HIV-1 particle [148], influenza A virus [149], and dengue virus [150]. While the immature HIV-1 particle included its viral matrix component, the influenza A virion did not explicitly include matrix protein 1 (M1, Figure 1a). The general lack of high-resolution structures for viral matrix assemblies represents another limiting factor in the construction of realistic all-atom virions.

In addition to suitable numbers and distributions of envelope proteins and viroporins embedded in the viral surface, truly complete and realistic virion models will also incorporate appropriate glycosylation on proteins and glycolipid species, as well as stoichiometric numbers of viral enzymes and accessory proteins encoded and packaged by the respective virus. The availability of in situ structures for intact virions, such as those recently obtained for HIV-1 using cryo-ET [151,152], will dramatically support future all-atom modeling and simulation efforts. Additionally, experimental characterization of viral envelope lipidomes and improved software and force fields for building and simulating large membrane assemblies [147] are essential advancements that will soon enable all-atom simulations of complete enveloped virions. Undoubtedly, all-atom virions will be among the first large-scale biological systems to be investigated on upcoming exascale supercomputing platforms.

## Acknowledgments

This work was supported by the National Institutes of Health grants P50GM082251 and P30GM110758-04 and the University of Delaware.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Goh B.C., Hadden JA, Bernardi RC, Singharoy A, McGreevy R, Rudack T, Keith Cassidy C, Schulten K: **Computational methodologies for real-space structural refinement of large macromolecular complexes.** *Annu Rev Biophys* 2016, **45**:253-278.
- A thorough review of integrative modeling and simulation approaches currently applied to determine and refine atomistic structures of large biological systems, including virus capsids.
2. Perilla J.R., Goh BC, Keith Cassidy C, Liu B., Bernardi RC, Rudack T, Yu H, Wu Z, Schulten K: **Molecular dynamics simulations of large macromolecular complexes.** *Curr Opin Struct Biol* 2015, **31**:64-74.
3. Harris A., Cardone G, Winkler DC, Bernard Heymann J, Brecher M., White JM, Steven AC: **Influenza virus pleiomorphy characterized by cryo-electron tomography.** *Proc Natl Acad Sci U S A* 2006, **103**:19123-19127.
4. Briggs J.A.G., Wilk T, Welker R, Kräusslich H-G, Fuller SD: **Structural organization of authentic, mature HIV-1 virions and cores.** *EMBO J* 2003, **22**:1707-1715.
5. Zeng Y., Larson SB, Heitsch CE, McPherson A, Harvey SC: **A model for the structure of satellite tobacco mosaic virus.** *J Struct Biol* 2012, **180**:110-116.
- All-atom modeling of STMV with its encapsidated RNA genome, producing the first realistic and chemically-complete structure of any virus.
6. Kasson P.M.: **Receptor binding by influenza virus: using computational techniques to extend structural data.** *Biochemistry* 2012, **51**:2359-2365.
7. Ji Y., White YJB, Hadden JA, Grant OC, Woods RJ: **New insights into influenza A specificity: an evolution of paradigms.** *Curr Opin Struct Biol* 2017, **44**:219-231.
8. Newhouse E.I., Xu D, Markwick PR, Amaro RE, Pao HC, Wu KJ, Alam M, McCammon JA, Li WW: **Mechanism of glycan receptor recognition and specificity switch for avian, swine, and human adapted influenza virus hemagglutinins: a molecular dynamics perspective.** *J Am Chem Soc* 2009, **131**:17430-17442.
9. Xu D., Newhouse EI, Amaro RE, Pao HC, Cheng LS, Markwick PR, McCammon JA, Li WW, Arzberger PW: **Distinct glycan topology for avian and human sialopentasaccharide receptor analogues upon binding different hemagglutinins: a molecular dynamics perspective.** *J Mol Biol* 2009, **387**:465-491.
10. Sieben C., Kappel C, Zhu R, Wozniak A, Rankl C, Hinterdorfer P, Grubmüller H, Herrmann A: **Influenza virus binds its host cell using multiple dynamic interactions.** *Proc Natl Acad Sci U S A* 2012, **109**:13626-13631.
11. Elli S., Macchi E, Rudd TR, Raman R, Sasaki G, Viswanathan K, Yates EA, Shriver Z, Naggi A, Torri G, Sasisekharan R, Guerrini M: **Insights into the human glycan receptor conformation of 1918 pandemic hemagglutinin-glycan complexes derived from nuclear magnetic resonance and molecular dynamics studies.** *Biochemistry* 2014, **53**:4122-4135.
12. Macchi E., Rudd TR, Raman R, Sasisekharan R, Yates EA, Naggi A, Guerrini M, Elli S: **Nuclear magnetic resonance and molecular dynamics simulation of the interaction between recognition protein H7 of the novel influenza virus H7N9 and glycan cell surface receptors.** *Biochemistry* 2016, **55**:6605-6616.
13. Peng W., de Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, Lee PS, Razi N, Wilson IA, Woods RJ et al.: **Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity.** *Cell Host Microbe* 2017, **21**:23-34.
14. De Vries R.P., Peng W, Grant OC, Thompson AJ, Zhu X, Bouwman KM, Torrents de la Pena AT, van Breemen M.J., Ambepitiya Wickramasinghe IN, de Haan C.A.M. et al.: **Three mutations switch H7N9 influenza to human-type receptor specificity.** *PLoS Pathogens* 2017, **13**:e1006390.
15. Kasson P.M., Ensign DL, Pande VS: **Combining molecular dynamics with Bayesian analysis to predict and evaluate ligand-binding mutations in influenza hemagglutinin.** *J Am Chem Soc* 2009, **131**:11338-11340.
16. Das P., Li J, Royyuru AK, Zhou R: **Free energy simulations reveal a double mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity.** *J Comput Chem* 2009, **30**:1654-1663.
17. Zhou R., Das P, Royyuru AK: **Single mutation induced H3N2 hemagglutinin antibody neutralization: a free energy perturbation study.** *J Phys Chem B* 2008, **112**:15813-15820.
18. Jeong P., Amaro RE, Li WW: **Molecular dynamics analysis of antibody recognition and escape by human H1N1 influenza hemagglutinin.** *Biophys J* 2015, **108**:2704-2712.
19. Kasson P.M., Pande VS: **Structural basis for influence of viral glycans on ligand binding by influenza hemagglutinin.** *Biophys J* 2008, **95**:L48-L50.
20. Khatri K., Klein JA, White MR, Grant OC, Leymarie N, Woods RJ, Hartshorn KL, Zaia J: **Integrated omics and computational glycobiology reveal structural basis for influenza a virus glycan microheterogeneity and host interactions.** *Mol Cell Proteom* 2016, **15**:1895-1912.
21. Goh B.C., Rynkiewicz MJ, Cafarella TR, White MR, Hartshorn KL, Allen K, Crouch EC, Calin O, Seeberger PH, Schulten K, Seaton BA: **Molecular mechanisms of inhibition of influenza by surfactant protein D revealed by large-scale molecular dynamics simulation.** *Biochemistry* 2013, **52**:8527-8538.

All-atom simulations of intact influenza HA complexed with an innate immune lectin, investigating the effects of lectin mutations on viral glycan attachment and inhibition of viral adhesion.

22. Huang Q., Chen C-L, Herrmann A: **Bilayer conformation of fusion peptide of influenza virus hemagglutinin: a molecular dynamics simulation study.** *Biophys J* 2004, **87**:14-22.
  23. Vaccaro L., Cross KJ, Kleinjung J, Straus SK, Thomas DJ, Wharton SA, Skehel JJ, Franterali F: **Plasticity of influenza hemagglutinin fusion peptides and their interaction with lipid bilayers.** *Biophys J* 2005, **88**:25-36.
  24. Lagüe P., Roux B, Pastor RW: **Molecular dynamics simulations of the influenza hemagglutinin fusion peptide in micelles and bilayers: conformational analysis of peptide and lipids.** *J Mol Biol* 2005, **354**:1129-1141.
  25. Jang H., Michaud-Agrawal N, Johnston J.M., Woolf TB: **How to lose a kink and gain a helix: pH independent conformational changes of the fusion domains from influenza hemagglutinin in heterogeneous lipid bilayers.** *Proteins: Struct Funct Bioinf* 2008, **72**:299-312.
  26. Kasson P.M., Lindahl E, Pande VS: **Atomic-resolution simulations predict a transition state for vesicle fusion defined by contact of a few lipid tails.** *PLoS Comput Biol* 2010, **6**: e1000829.
  27. Legare S., Lagüe P: **The influenza fusion peptide adopts a flexible flat V conformation in membranes.** *Biophys J* 2012, **102**:2270-2278.
  28. Kalani M.R., Moradi A, Moradi M, Tajkhorshid E: **Characterizing a histidine switch controlling pH-dependent conformational changes of the influenza virus hemagglutinin.** *Biophys J* 2013, **105**:993-1003.
  29. Larsson P., Kasson PM: **Lipid tail protrusion in simulations predicts fusogenic activity of influenza fusion peptide mutants and conformational models.** *PLoS Comput Biol* 2013, **9**: e1002950.
  30. Legaré S, Lagüe P.: **The influenza fusion peptide promotes lipid polar head intrusion through hydrogen bonding with phosphates and N-terminal membrane insertion depth.** *PROTEINS: Struct Funct Bioinf* 2014, **82**:2118-2127.
  31. Zhou Y., Wu C, Zhao L, Huang N: **Exploring the early stages of the pH-induced conformational change of influenza hemagglutinin.** *Proteins: Struct Funct Bioinform* 2014, **82**:2412-2428.
  32. Brice A.R., Lazaridis T: **Structure and dynamics of a fusion peptide helical hairpin on the membrane surface: comparison of molecular simulations and NMR.** *J Phys Chem B* 2014, **118**:4461-4470.
  33. Beck C.R., Sokal R, Arunachalam N, Puleston R, Cichowska A, Kessel A, Zambon M, Nguyen-Van-Tam JS: **Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.** *Influenza Other Respir Viruses* 2013, **7**:14-24.
  34. Amaro R.E., Minh DDL, Cheng LS Jr, Olson William AJ, Lindstrom M, Lin J.-H., Liand WW, McCammon JA: **Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design.** *J Am Chem Soc* 2007, **129**:7764-7765.
  35. Amaro RE, Cheng X, Ivanov I, Xu D, McCammon JA: **Characterizing loop dynamics and ligand recognition in human-and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations.** *J Am Chem Soc* 2009, **131**:4702-4709.
  36. Lawrenz M, Baron R, McCammon JA: **Independent-trajectories thermodynamic-integration free-energy changes for biomolecular systems: determinants of H5N1 avian influenza virus neuraminidase inhibition by peramivir.** *J Chem Theory Comput* 2009, **5**:1106-1116.
  37. Amaro R.E., Swift RV, Votapka L, Li WW, Walker RC, Bush RM: **Mechanism of 150-cavity formation in influenza neuraminidase.** *Nat Commun* 2011, **2**:388.
  38. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA: **Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.** *J Med Chem* 2008, **51**:3878-3894.
  39. Landon M.R., Amaro RE, Baron R, Ho-Ngan C, Ozonoff D, Andrew McCammon J, Vajda S.: **Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.** *Chem Biol Drug Des* 2008, **71**:106-116.
  40. Durrant J.D., Andrew McCammon J: **Potential drug-like inhibitors of group 1 influenza neuraminidase identified through computer-aided drug design.** *Comput Biol Chem* 2010, **34**:97-105.
  41. Le L., Lee EH, Schulten K, Truong T: **Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza.** *PLoS Curr: Influenza* 2009, **1**:RRN1015.
  42. Le L, Lee EH, Hardy DJ, Truong TN, Schulten K: **Molecular dynamics simulations suggest that electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases.** *PLoS Comput Biol* 2010, **6**:e1000939.
  43. Vergara-Jaque A, Poblete H, Lee E, Schulten K, Gonzalez-Nilo F, Chipot C: **Molecular basis of drug resistance in A/H1N1 virus.** *J Chem Inf Model* 2012, **52**:2650-2656.
  44. Lawrenz M, Wereszczynski J, Amaro R, Walker R, Roitberg A, McCammon JA: **Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.** *Proteins: Struct Funct Bioinform* 2010, **78**:2523-2532.
  45. Durrant J.D., Bush RM, Amaro RE: **Microsecond molecular dynamics simulations of influenza neuraminidase suggest a mechanism for the increased virulence of stalk-deletion mutants.** *J Phys Chem B* 2016, **120**:8590-8599.
- All-atom simulations of intact influenza NA embedded in a realistic envelope bilayer, investigating druggability and the relationship between stalk length and virulence.
46. Yokoyama M., Naganawa S, Yoshimura K, Matsushita S, Sato H: **Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop.** *PLoS ONE* 2012, **7**:e37530.
  47. de Victoria A.L., Tamamis P, Kieslich CA, Morikis D: **Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops.** *PLoS ONE* 2012, **7**:e49925.
  48. Shrivastava I., LaLonde JM: **Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network.** *Proteins: Struct Funct Bioinform* 2010, **78**:2935-2949.
  49. Sethi A., Tian J, Derdeyn CA, Korber B, Gnanakaran S: **A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein.** *PLoS Comput Biol* 2013, **9**:e1003046.
  50. Lemmin T., Soto C, Stuckey J, Kwong PD: **Microsecond dynamics and network analysis of the HIV-1 SOSIP Env trimer reveal collective behavior and conserved microdomains of the glycan shield.** *Structure* 2017, **25**:1631-1639.
  51. Kamath S., Wong TC: **Membrane structure of the human immunodeficiency virus gp41 fusion domain by molecular dynamics simulation.** *Biophys J* 2002, **83**:135-143.
  52. Wong T.C.: **Membrane structure of the human immunodeficiency virus gp41 fusion peptide by molecular dynamics simulation: II. The glycine mutants.** *Biochim Biophys Acta* 2003, **1609**:45-54.
  53. Kim J.H., Hartley TL, Rachael Curran A, Engelman DM: **Molecular dynamics studies of the transmembrane domain of gp41 from hiv-1.** *Biochim Biophys Acta* 2009, **1788**:1804-1812.
  54. Gangupomu V.K., Abrams CF: **All-atom models of the membrane-spanning domain of HIV-1 gp41 from metadynamics.** *Biophys J* 2010, **99**:3438-3444.
  55. Apellániz B., Rujas E, Carravilla P, Requejo-Isidro J, Huarte N, Domene C, Nieva JL: **Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-**

- transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization. *J Virol* 2014, **88**:13367-13377.
56. Baker M.K., Gangupomu VK, Abrams CF: **Characterization of the water defect at the HIV-1 gp41 membrane spanning domain in bilayers with and without cholesterol using molecular simulations.** *Biochim Biophys Acta* 2014, **1838**:1396-1405.
  57. Doores KJ: **The HIV glycan shield as a target for broadly neutralizing antibodies.** *FEBS J* 2015, **282**:4679-4691.
  58. Wood N.T., Fadda E, Davis R, Grant OC, Martin JC, Woods RJ, Travers SA: **The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop.** *PLoS ONE* 2013, **8**:e80301.
  59. Qi Y., Jo S, Im W: **Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.** *Glycobiology* 2016, **26**:251-260.
  60. Tian J., López CA, Derdeyn CA, Jones MS, Pinter A, Korber B, Gnanakaran S: **Effect of glycosylation on an immunodominant region in the V1V2 variable domain of the HIV-1 envelope gp120 protein.** *PLoS Comput Biol* 2016, **12**:e1005094.
  61. Stewart-Jones G.B.E., Soto C, Lemmin T, Chuang G-Y, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens A-J, By-Lund T, Choi CW, Davison JR, Georgiev IS, Gordon Joyce M, Do Kwon Y, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee C-CD, Wu C-Y, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong C-H, Mascola JR, Wong PDK: **Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G.** *Cell* 2016, **165**:813-826.
- All-atom simulations of multiple glycoforms of intact HIV-1 Env, investigating the dynamics of the glycan shield, as well as glycan involvement in antibody recognition.
62. Li X., Grant OC, Ito K, Wallace A, Wang S, Zhao P, Wells L, Lu S, Woods RJ, Sharp JS: **Structural analysis of the glycosylated intact HIV-1 gp120-b12 antibody complex using hydroxyl radical protein footprinting.** *Biochemistry* 2017, **56**:957-970.
  63. Zhou T., Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang G-Y, Chambers M, Druz A, Geng H, McKee K, Do Kwon Y *et al.*: **Quantification of the impact of the HIV-1-glycan shield on antibody elicitation.** *Cell Rep* 2017, **19**:719-732.
  64. Kampmann T, Mueller DS, Mark AE, Young PR, Kobe B: **The role of histidine residues in low-pH-mediated viral membrane fusion.** *Structure* 2006, **14**:1481-1487.
  65. Mueller DS, Kampmann T, Yennamalli R, Young PR, Kobe B, Mark AE: **Histidine protonation and the activation of viral fusion proteins.** *Biochemistry* 2008, **36**:43-45.
  66. Prakash MK, Barducci A, Parrinello M: **Probing the mechanism of pH-induced large scale conformational change in the dengue virus envelope protein using atomistic simulations.** *Biophysics* 2010, **99**:588-594.
  67. Dubey K.D., Chaubey AK, Ojha RP: **Role of pH on dimeric interactions for DENV envelope protein: an insight from molecular dynamics study.** *Biochim. Biophys. Acta-Proteins Proteom* 2011, **1814**:1796-1801.
  68. Fuzo C.A., Degrève L: **New pockets in dengue virus 2 surface identified by molecular dynamics simulation.** *J Mol Model* 2013, **19**:1369-1377.
  69. Degrève L., Fuzo CA *et al.*: **Structure and dynamics of the monomer of protein E of dengue virus type 2 with unprotonated histidine residues.** *Genet Mol Res* 2013, **12**:348-359.
  70. Rucker P., Wieninger SA, Matthias Ullmann G, Sticht H.: **pH-dependent molecular dynamics of vesicular stomatitis virus glycoprotein G.** *Proteins: Struct Funct Bioinform* 2012, **80**:2601-2613.
  71. Freitas M.S., Gaspar LP, Lorenzoni M, Almeida FCL, Tinoco LW, Almeida MS, Maia LF, Degrève L, Valente AP, Silva JL: **Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts.** *J Biol Chem* 2007, **282**:27306-27314.
  72. Jaskierny A.J., Panahi A, Feig M: **Effect of flanking residues on the conformational sampling of the internal fusion peptide from Ebola virus.** *Proteins: Struct Funct Bioinform* 2011, **79**:1109-1117.
  73. Gregory S.M., Larsson P, Nelson EA, Kasson PM, White JM, Tamm LK: **Ebolavirus entry requires a compact hydrophobic fist at the tip of the fusion loop.** *J Virol* 2014, **88**:6636-6649.
  74. Vitiello G., Falanga A, Alcides Petruk A, Merlino A, Fragneto G, Paduano L, Galdiero S, D'Errico G: **Fusion of raft-like lipid bilayers operated by a membranotropic domain of the HSV-type I glycoprotein gH occurs through a cholesterol-dependent mechanism.** *Soft Matter* 2015, **11**:3003-3016.
  75. Winger M., von Itzstein M: **Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase.** *J Am Chem Soc* 2012, **134**:18447-18452.
  76. Kong L., Lee DE, Kadam RU, Liu T, Giang E, Nieuwsma T, Garces F, Tzarum N, Woods VL, Ward AB *et al.*: **Structural flexibility at a major conserved antibody target on hepatitis C virus e2 antigen.** *Proc Natl Acad Sci U S A* 2016, **113**:12768-12773.
  77. Barone D., Balasco N, Autiero I, Vitagliano L: **The dynamic properties of the hepatitis C virus e2 envelope protein unraveled by molecular dynamics.** *J Biomol Struct Dyn* 2017, **35**:805-816.
  78. Nieva J.L., Madan V, Carrasco L: **Viroporins: structure and biological functions.** *Nat Rev Microbiol* 2012, **10**:563.
  79. Cady S.D., Luo W, Hu F, Hong M: **Structure and function of the influenza A M2 proton channel.** *Biochemistry* 2009, **48**:7356-7364.
  80. Schweighofer K.J., Pohorille A: **Computer simulation of ion channel gating: the M2 channel of influenza A virus in a lipid bilayer.** *Biophys J* 2000, **78**:150-163.
  81. Smondryev AM, Voth GA: **Molecular dynamics simulation of proton transport through the influenza A virus M2 channel.** *Biophys J* 2002, **83**:1987-1996.
  82. Wu Y., Voth GA: **A computational study of the closed and open states of the influenza a M2 proton channel.** *Biophys J* 2005, **89**:2402-2411.
  83. Chen H., Wu Y, Voth GA: **Proton transport behavior through the influenza a M2 channel: insights from molecular simulation.** *Biophys J* 2007, **93**:3470-3479.
  84. Yi M., Cross TA, Zhou H-X: **A secondary gate as a mechanism for inhibition of the M2 proton channel by amantadine.** *J Phys Chem B* 2008, **112**:7977-7979.
  85. Yi M., Cross TA, Zhou H-X: **Conformational heterogeneity of the M2 proton channel and a structural model for channel activation.** *Proc Natl Acad Sci U S A* 2009, **106**:13311-13316.
  86. Liang R., Li H, Swanson JMJ, Voth GA: **Multiscale simulation reveals a multifaceted mechanism of proton permeation through the influenza a M2 proton channel.** *Proc Natl Acad Sci U S A* 2014, **111**:9396-9401.
  87. Zhong Q., Newns DM, Pattnaik P, Lear JD, Klein ML: **Two possible conducting states of the influenza A virus M2 ion channel.** *FEBS Lett* 2000, **473**:195-198.
  88. Khurana E., Dal Peraro M, DeVane R, Vemparala S, DeGrado WF, Klein ML: **Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus.** *Proc Natl Acad Sci U S A* 2009, **106**:1069-1074.
  89. Thomaston J.L., Alfonso-Prieto M, Woldeyes RA, Fraser JS, Klein ML, Fiorin G, DeGrado WF: **High-resolution structures of the M2 channel from influenza A virus reveal dynamic pathways for proton stabilization and transduction.** *Proc Natl Acad Sci U S A* 2015, **112**:14260-14265.
  90. Khurana E., DeVane RH, Dal Peraro M, Klein ML: **Computational study of drug binding to the membrane-bound tetrameric M2 peptide bundle from influenza A virus.** *Biochim Biophys Acta* 2011, **1808**:530-537.
  91. Leonov H., Astrahan P, Krugliak M, Arkin IT: **How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?** *J Am Chem Soc* 2011, **133**:9903-9911.

92. Gu R.-X., Angela Liu L, Wang Y-H, Xu Q, Wei D-Q: **Structural comparison of the wild-type and drug-resistant mutants of the influenza A M2 proton channel by molecular dynamics simulations.** *J Phys Chem B* 2013, **117**:6042-6051.
93. Wang J., Ma C, Fiorin G, Carnevale V, Wang T, Hu F, Lamb RA, Pinto LH, Hong M, Klein ML *et al.*: **Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2.** *J Am Chem Soc* 2011, **133**:12834-12841.
94. Wang J., Wu Y, Ma C, Fiorin G, Wang J, Pinto LH, Lamb RA, Klein ML, DeGrado WF: **Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.** *Proc Natl Acad Sci U S A* 2013, **110**:1315-1320.
95. Fischer W.B.: **Vpu from HIV-1 on an atomic scale: experiments and computer simulations.** *FEBS Lett* 2003, **552**:39-46.
96. Lopez C.F., Montal M, Kent Blasie J, Klein ML, Moore PB: **Molecular dynamics investigation of membrane-bound bundles of the channel-forming transmembrane domain of viral protein U from the human immunodeficiency virus HIV-1.** *Biophys J* 2002, **83**:1259-1267.
97. Hertel B., Tayefeh S, Kloss T, Hewing J, Gebhardt M, Baumeister D, Moroni A, Thiel G, Kast SM: **Salt bridges in the miniature viral channel Kcv are important for function.** *Eur Biophys J* 2010, **39**:1057-1068.
98. Gebhardt M., Hoffgaard F, Hamacher K, Kast SM, Moroni A, Thiel G: **Membrane anchoring and interaction between transmembrane domains are crucial for K<sup>+</sup> channel function.** *J Biol Chem* 2011, **286**:11299-11306.
99. Tayefeh S., Kloss T, Kreim M, Gebhardt M, Baumeister D, Hertel B, Richter C, Schwalbe H, Moroni A, Thiel G *et al.*: **Model development for the viral Kcv potassium channel.** *Biophys J* 2009, **96**:485-498.
100. Montserret R., Saint N, Vanbelle C, Gerardo Salvay A, Simorre J-P, Ebel C, Sapay N, Renisio J-G, Böckmann A, Steinmann E, Pietschmann T, Dubuisson J, Chipot C, Penin F: **NMR structure and ion channel activity of the p7 protein from hepatitis C virus.** *J Biol Chem* 2010, **285**:31446-31461.
101. Chandler D.E., Penin F, Schulten K, Chipot C: **The p7 protein of hepatitis C virus forms structurally plastic, minimalist ion channels.** *PLoS Comput Biol* 2012, **8**:e1002702.
- All-atom simulations of HCV p7 viroporin embedded in membrane bilayers, elucidating likely oligomeric states and functional ion channel characteristics.
102. Wang Y.-T., Schilling R, Fink RHA, Fischer WB: **Ion-dynamics in hepatitis C virus p7 helical transmembrane domains: a molecular dynamics simulation study.** *Biophys Chem* 2014, **192**:33-40.
103. Cook G.A., Dawson LA, Tian Y, Opella SJ: **Three-dimensional structure and interaction studies of hepatitis C virus p7 in 1,2-dihexanoyl-sn-glycero-3-phosphocholine by solution nuclear magnetic resonance.** *Biochemistry* 2013, **52**:5295-5303.
104. Mon Kalita M., Griffin S, Chou JJ, Fischer WB: **Genotype-specific differences in structural features of hepatitis C virus (HCV) p7 membrane protein.** *Biochim Biophys Acta* 2015, **1848**:1383-1392.
105. Mon Kalita M., Fischer WB: **Asymmetric dynamics of ion channel forming proteins hepatitis C virus (HCV) p7 bundles.** *Biochim Biophys Acta* 2016, **1858**:1462-1470.
106. May E.R.: **Recent developments in molecular simulation approaches to study spherical virus capsids.** *Mol Simul* 2014, **40**:878-888.
107. Perilla J.R., Hadden JA, Goh BC, Mayne C.G., Schulten K: **All-atom molecular dynamics of virus capsids as drug targets.** *J Phys Chem Lett* 2016, **7**:1836-1844.
- A perspective on applying all-atom simulations to study drug-bound capsids, demonstrating that chemical resolution is required to achieve accurate characterization of protein-ligand interactions.
108. Freddolino P.L., Arkhipov AS, Larson SB, McPherson A, Schulten K: **Molecular dynamics simulations of the complete satellite tobacco mosaic virus.** *Structure* 2006, **14**:437-449.
- The first all-atom simulations of an intact capsid and complete virion, demonstrating the role of packaged genome in the structural stability of STMV.
109. Zink M., Grubmüller H: **Mechanical properties of the icosahedral shell of southern bean mosaic virus: a molecular dynamics study.** *Biophys J* 2009, **96**:1350-1363.
110. May E.R., Brooks CL III: **Determination of viral capsid elastic properties from equilibrium thermal fluctuations.** *Phys Rev Lett* 2011, **106**:188101.
111. Wang X., Xu F, Liu J, Gao B, Liu Y, Zhai Y, Ma J, Zhang K, Baker TS, Schulten K, Zheng D, Pang H, Sun F: **Atomic model of rabbit hemorrhagic disease virus by cryo-electron microscopy and crystallography.** *PLoS Pathogens* 2013, **9**:e1003132.
112. Tarasova E, Farafonov V, Khayat R, Okimoto N, Komatsu TS, Tajji M, Nerukh D: **All-atom molecular dynamics simulations of entire virus capsid reveal the role of ion distribution in capsid's stability.** *J Phys Chem Lett* 2017, **8**:779-784.
113. Tarasova E., Korotkin I, Farafonov V, Karabasov S, Nerukh D: **Complete virus capsid at all-atom resolution: Simulations using molecular dynamics and hybrid molecular dynamics/hydrodynamics methods reveal semipermeable membrane function.** *J Mol Liquids* 2017, **245**:109-114.
114. Larsson D.S.D., Liljas L, van der Spoel D: **Virus capsid dissolution • studied by microsecond molecular dynamics simulations.** *PLoS Comput Biol* 2012, **8**:e1002502.
- The first all-atom simulations of an intact capsid to reach the microsecond timescale, revealing the mechanistic pathway for STNV swelling in the absence of structural calcium ions.
115. Andoh Y., Yoshii N, Yamada A, Fujimoto K, Kojima H, Mizutani K, Nakagawa A, Nomoto A, Okazaki S: **All-atom molecular dynamics calculation study of entire poliovirus empty capsids in solution.** *J Chem Phys* 2014, **141**:165101.
116. Hadden J.A., Perilla JR, John Schlicksup C, Venkatakrishnan B., Zlotnick A., Schulten K: **All-atom molecular dynamics of the HBV capsid reveals insights into biological function and cryo-EM resolution limits.** *eLife* 2018, **7**:e32478.
- All-atom simulations of the HBV capsid over one microsecond, revealing flexibility and asymmetry in an icosahedral structure, with implications for resolution of single-particle image reconstructions.
117. Ruan L., Hadden JA, Zlotnick A: **Assembly properties of Hepatitis B Virus core protein mutants correlate with their resistance to assembly-directed antivirals.** *J Virol* 2018:JV1-01082. (in press).
118. Zhao G., Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, Gronenborn AM, Schulten K, Aiken C, Zhang P: **Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics.** *Nature* 2013, **497**:643-646.
- A landmark publication for computational virology, presenting an all-atom structure of the HIV-1 capsid derived from data-guided modeling and simulations totaling 64 million particles.
119. Liu C., Perilla JR, Ning J, Lu M, Hou G, Ramalho R, Bedwell G, Byeon I-J, Ahn J, Shi J, Gronenborn A, Prevelige P, Rousso I, Aiken C, Polenova T, Schulten K, Zhang P: **Cyclophilin A stabilizes HIV-1 capsid through a novel non-canonical binding site.** *Nat Commun* 2016, **7**:10714.
120. Lu M, Hou G, Zhang H, Suiter CL, Ahn J, Byeon I-JL, Perilla JR, Langmead CJ, Hung I, Gor'kov PL, Gan Z, Brey W, Aiken C, Zhang P, Schulten K, Gronenborn AM, Polenova T: **Dynamic allostery governs cyclophilin A-HIV capsid interplay.** *Proc Natl Acad Sci U S A* 2015, **112**:14617-14622.
121. Alvarez F.J.D., He S, Perilla JR, Jang S, Schulten K, Engelman AN, Sc heres SHW, Zhang P: **CryoEM structure of MxB reveals a novel oligomerization interface critical for HIV restriction.** *Sci Adv* 2017, **3**:e1701264.
122. Perilla JR, Schulten K.: **Physical properties of the HIV-1 capsid • from all-atom molecular dynamics simulations.** *Nat Commun* 2017, **8**:15959.
- The most substantial all-atom MD study ever reported, employing simulations of the HIV-1 capsid system of 64 million particles over one microsecond to investigate its biophysical properties.

123. Perilla J.R., Gronenborn AM: **Molecular architecture of the retroviral capsid.** *Trends Biochem Sci* 2016, **41**:410-420.
124. Martin JL, Mendonca L, Marusinec R, Zuczek J, Angert I, Blower RJ, Mueller JD, Perilla JR, Zhang W, Mansky LM: **Critical role of the HTLV-1 capsid n-terminal domain for Gag-Gag interactions and virus particle assembly.** *J Virol* 2018. JVI-00333.
125. Goh B.C., Perilla JR, England MR, Heyrana KJ, Craven RC, Schulten K: **Atomic modeling of an immature retroviral lattice using molecular dynamics and mutagenesis.** *Structure* 2015, **23**:1414-1425.
126. Wang M., Quinn CM, Perilla JR, Zhang H, Shirra R Jr, Hou G, Byeon I-J, Suiter CL, Ablan S, Urano E *et al.*: **Quenching protein dynamics interferes with HIV capsid maturation.** *Nature Commun* 2017, **8**:1779.
- All-atom simulated tempering of the HIV-1 CA-SP1 hexamer on ANTON2, revealing that the structure of the six-helix bundle is characterized by a dynamic helix-coil equilibrium.
127. Dick R, Zadrozny K, Xu C, Schur F, Lyddon T, Ricana C, Wagner J, Perilla J, Ganser-Pornillos B, Johnson M, Pornillos O, Vogt V: **Inositol phosphates are assembly co-factors for HIV-1** *Nature* **560**: 509-512 All-atom simulations of the HIV-1 CA-SP1 hexamer in complex with inositol phosphates, revealing the mechanism by which they promote assembly of the immature virus particle.
128. Heyrana K.J., Goh BC, Perilla JR, Nguyen T-LN, England MR, Bewley MC, Schulten K, Craven RC: **Contributions of charged residues in structurally dynamic capsid surface loops to Rous sarcoma virus assembly.** *J Virol* 2016, **90**:5700-5714.
129. Collins J.R., Burt SK, Erickson JW: **Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics.** *Nat Struct Biol* 1995, **2**:334-338.
130. Hornak V., Okur A, Rizzo RC, Simmerling C: **HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations.** *Proc Natl Acad Sci U S A* 2006, **103**:915-920.
131. Hornak V., Okur A, Rizzo RC, Simmerling C: **Hiv-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state.** *J Am Chem Soc* 2006, **128**:2812-2813.
132. Ding F., Layten M, Simmerling C: **Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments.** *J Am Chem Soc* 2008, **130**:7184-7185.
133. Deng N.-J., Zheng W, Gallicchio E, Levy RM: **Insights into the dynamics of hiv-1 protease: a kinetic network model constructed from atomistic simulations.** *J Am Chem Soc* 2011, **133**:9387-9394.
134. Kashif Sadiq S., Noé F, De Fabritiis G: **Kinetic characterization of the critical step in HIV-1 protease maturation.** *Proc Natl Acad Sci U S A* 2012, **109**:20449-20454.
135. Ekonomiuk D., Caffisch A: **Activation of the West Nile virus NS3 protease: molecular dynamics evidence for a conformational selection mechanism.** *Protein Sci* 2009, **18**:1003-1011.
136. Ivetac A., McCammon JA: **Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations.** *J Mol Biol* 2009, **388**:644-658.
137. Devkota B., Petrov AS, Lemieux S, Burak Boz M, Tang L, Schneemann A, Johnson JE, Harvey SC: **Structural and electrostatic characterization of *Pariacoto* virus: implications for viral assembly.** *Biopolymers* 2009, **91**:530-538.
138. Larson SB, McPherson A: **Satellite tobacco mosaic virus RNA: structure and implications for assembly.** *Curr Opin Struct Biol* 2001, **11**:59-65.
139. Tang L., Johnson KN, Andrew Ball L, Lin T., Yeager M, Johnson JE: **The structure of pariacoto virus reveals a dodecahedral cage of duplex RNA.** *Nat Struct Biol* 2001, **8**:77-83.
140. Zhang H., Hou G, Lu M, Ahn J, Byeon I-JL, Langmead CJ, Perilla JR, Hung I, Gor'kov PL, Gan Z, Brey WW, Case DA, Schulten K, Gronenborn AM, Polenova T: **HIV-1 capsid function is regulated by dynamics: Quantitative atomic-resolution insights by integrating magic-angle-spinning NMR, QM/MM, and MD.** *J Am Chem Soc* 2016, **138**:14066-14075.
141. Perilla J.R., Zhao G, Lu M, Ning J, Hou G, Byeon I-JL, Gronenborn AM, Polenova T, Zhang P: **CryoEM structure refinement by integrating NMR chemical shifts with molecular dynamics simulations.** *J Phys Chem B* 2017, **121**:3853-3863.
142. Wang JC-Y, Nickens DG, Lentz TB, Loeb DD, Zlotnick A: **Encapsidated hepatitis B virus reverse transcriptase is poised on an ordered RNA lattice.** *Proc Natl Acad Sci U S A* 2014, **111**:11329-11334.
143. Dai X., Li Z, Lai M, Shu S, Du Y, Zhou ZH, Sun R: **In situ structures of the genome and genome-delivery apparatus in a single-stranded RNA virus.** *Nature* 2017, **541**:112.
144. Harvey S.C., Zeng Y, Heitsch CE: **The icosahedral RNA virus as a grotto: organizing the genome into stalagmites and stalactites.** *J Biol Phys* 2013, **39**:163-172.
145. Huang J., Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubmüller H, MacKerell AD Jr: **Charmm36m: an improved force field for folded and intrinsically disordered proteins.** *Nat Methods* 2017, **14**:71.
146. Tan D., Piana S, Dirks RM, Shaw DE: **RNA force field with accuracy comparable to state-of-the-art protein force fields.** *Proc Natl Acad Sci U S A* 2018, **115**:1346-1355.
147. Reddy T, Sansom MSP: **Computational virology: from the inside out.** *Biochim Biophys Acta* 2016, **1858**:1610-1618.
148. Ayton GS, Voth GA: **Multiscale computer simulation of the immature HIV-1 virion.** *Biophys J* 2010, **99**:2757-2765.
149. Reddy T., Shorthouse D, Parton DL, Jefferys E, Fowler PW, Chavent M, Baaden M, Sansom MSP: **Nothing to sneeze at: a dynamic and integrative computational model of an influenza a virion.** *Structure* 2015, **23**:584-597.
150. Reddy T., Sansom MSP: **The role of the membrane in the structure and biophysical robustness of the dengue virion envelope.** *Structure* 2016, **24**:375-382.
151. Schur F.K.M., Hagen WJH, Rumlova M, Ruml T, Muller B, Krausslich H-G, Briggs JAG: **Structure of the immature HIV-1 capsid in intact virus particles at 8.8 Å resolution.** *Nature* 2015, **517**:505-508.
152. Mattei S., Glass B, Hagen WJH, Kräusslich H-G, Briggs JAG: **The structure and flexibility of conical HIV-1 capsids determined within intact virions.** *Science* 2016, **354**:1434-1437.